## GSK1904529A

Cat. No.:	HY-10524		
CAS No.:	1089283-49-	-7	
Molecular Formula:	C <sub>44</sub> H <sub>47</sub> F <sub>2</sub> N <sub>9</sub> O	₅S	
Molecular Weight:	851.96		
Target:	IGF-1R; Insulin Receptor; Apoptosis		
Pathway:	Protein Tyrosine Kinase/RTK; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year

®

MedChemExpress

### SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (58	DMSO : 50 mg/mL (58.69 mM; Need ultrasonic)					
		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	1.1738 mL	5.8688 mL	11.7376 mL		
		5 mM	0.2348 mL	1.1738 mL	2.3475 mL		
		10 mM	0.1174 mL	0.5869 mL	1.1738 mL		
	Please refer to the so	Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent o Solubility: ≥ 2.75 n	one by one: 10% DMSO >> 40% PEC ng/mL (3.23 mM); Clear solution	6300 >> 5% Tween-80	) >> 45% saline			

Description	GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR), with IC <sub>50</sub> s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC <sub>50</sub> >1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity <sup>[1][2]</sup> .		
IC <sub>50</sub> & Target	IC50: 27 nM (IGF-1R), 25 nM (IR) <sup>[1]</sup>		
In Vitro	GSK1904529A displays high affinities for IGF-1R and IR, with K <sub>i</sub> s of 1.6 and 1.3 nM, respectively <sup>[1]</sup> . GSK1904529A (72 h) inhibits tumor cells proliferation with IC <sub>50</sub> s ranges from 35 nM to >30 μM, and Ewing's sarcoma and multiple myeloma cell lines are greatest sensitive <sup>[1]</sup> . GSK1904529A (0.03-3 μM; 24 and 48 h) arrests cells at the G1 phase of the cell cycle <sup>[1]</sup> . GSK1904529A (2 h) inhibits phosphorylation of IGF-IR and IR with IC <sub>50</sub> s of 22 and 19 nM in NIH-3T3/LISN and NIH-3T3-hIR cells, respectively <sup>[1]</sup> .		

# Product Data Sheet

GSK1904529A (0.01-3  $\mu$ M; 4 h) blocks the major downstream signal transduction pathways mediated by IGF-IR and IR in NIH-3T3/LISN and NIH-3T3-hIR cells<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis<sup>[1]</sup>

Cell Line:	COLO 205, MCF-7, and NCI-H929 cells
Concentration:	0, 0.03, 0.1, 0.3, 1, 3 μM
Incubation Time:	24 and 48 hours
Result:	Increased the accumulation in G1 and decreased accumulation in S and G2-M phases of the cell cycle.
Western Blot Analysis <sup>[1]</sup>	
Cell Line:	NIH-3T3/LISN and NIH-3T3-hIR cells
Concentration:	0.01, 0.03, 0.1, 0.3, 1, 3 μM
Incubation Time:	4 hours
Result:	Inhibited the ligand-induced phosphorylation of IGF-IR and IR at concentrations >0.01 $\mu M$ Decreased the phosphorylation of AKT, IRS-1, and ERK.

In Vivo

GSK1904529A (30 mg/kg; p.o. once or twice daily for 21 d) has antitumor activity in mice<sup>[1]</sup>.

GSK1904529A (1-30 mg/kg; a single p.o.) decreases IGF-I-induced IGF-IR phosphorylation in a dose-dependent manner in mice<sup>[1]</sup>.

GSK1904529A (30 mg/kg; p.o. once or twice daily for 21 d) has no significant alterations in the blood glucose levels in mice<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female athymic nu/nu CD-1 mice are bring NIH-3T3/LISN tumor $^{[1]}$
Dosage:	30 mg/kg
Administration:	P.o. once or twice daily for 21 d
Result:	Resulted in 56% (once daily) and 98% (twice daily) inhibition of tumor growth. No significant decrease in body weight on the once-daily schedule. Observed 11-13% of body weight loss, and recovered to near baseline 6 days after the cessation of treatment in twice-daily group.

#### **CUSTOMER VALIDATION**

- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Clin Cancer Res. 2014 Nov 1;20(21):5483-95.
- Open Biol. 2023 Oct;13(10):230336.
- iScience. 2022 Apr 18;25(5):104267.
- J Cell Mol Med. 2021 Apr;25(7):3205-3215.

See more customer validations on www.MedChemExpress.com

#### REFERENCES

[1]. Sabbatini P, et al. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res, 2009, 15(9), 3058-3067.

[2]. Zhou Q, et, al. GSK1904529A, an insulin-like growth factor-1 receptor inhibitor, inhibits glioma tumor growth, induces apoptosis and inhibits migration. Mol Med Rep. 2015 Sep;12(3):3381-3385.

#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA